Tvardi Therapeutics (TVRD) Receivables (2014 - 2025)
Tvardi Therapeutics (TVRD) posted Receivables of $2.2 million for Q1 2025, up 241.68% sequentially from $655000.0 in Q4 2024, and up 0.63% YoY from $2.2 million in Q1 2024.
Tvardi Therapeutics (TVRD) Receivables (2014 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Receivables for 10 years, with the latest figure at $2.2 million in Q1 2025.
- Quarterly Receivables rose 0.63% year-over-year to $2.2 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $2.2 million (up 0.63% YoY) and the FY2024 annual result came in at $4.5 million, up 35.39% from the prior year.
- Receivables climbed to $2.2 million in Q1 2025 per TVRD's latest filing, from $655000.0 in the prior quarter.
- Over five years, Receivables peaked at $40.1 million in Q3 2021 and troughed at -$19.9 million in Q4 2021.
- A 5-year average of $4.2 million and a median of $2.2 million in 2024 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 8574.46% in 2021, down 21042.11% in 2021.
- Over 5 years, Receivables stood at -$19.9 million in 2021, then soared by 100.23% to $45000.0 in 2022, then surged by 3540.0% to $1.6 million in 2023, then slumped by 60.01% to $655000.0 in 2024, then soared by 241.68% to $2.2 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $2.2 million, $655000.0, and $1.4 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.24 Mn |
| Dec 31, 2024 | 655,000.00 |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 2.22 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 5.03 Mn |
| Jun 30, 2023 | 10.12 Mn |
| Mar 31, 2023 | 6.07 Mn |
| Dec 31, 2022 | 45,000.00 |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 438,000.00 |
| Dec 31, 2021 | -19.90 Mn |
| Sep 30, 2021 | 40.08 Mn |
| Jun 30, 2021 | 305,000.00 |
| Mar 31, 2021 | 2.24 Mn |
| Dec 31, 2020 | 95,000.00 |
| Sep 30, 2020 | 462,000.00 |
| Jun 30, 2020 | 486,000.00 |